Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

This article is part of the supplement: Breast Cancer Research 2010

Poster presentation

Insulin-like growth factor binding protein-2 alters the sensitivity of breast cancer cells to chemotherapy

EJ Foulstone*, JM Holly, L Zeng, ZE Winters and CM Perks

  • * Corresponding author: EJ Foulstone

Author Affiliations

University of Bristol, UK

For all author emails, please log on.

Breast Cancer Research 2010, 12(Suppl 1):P22  doi:10.1186/bcr2519

The electronic version of this article is the complete one and can be found online at: http://breast-cancer-research.com/content/12/S1/P22


Published:18 May 2010

© 2010 BioMed Central Ltd.

Introduction

Insulin-like growth factor binding protein-2 (IGFBP-2) is often elevated in breast tumours and the presence of IGFBP-2 has been shown to correlate with malignancy. Previously we have shown that IGFBP-2 reduces PTEN abundance [1] and thus helps to maintain the activity of the phosphoinositide 3-kinase signalling cascade, a key mitogenic and survival pathway.

Objective

We therefore investigated whether IGFBP-2 could act as a survival factor for breast cancer cell lines. Using MCF7 and T47D cells, we tested the ability of exogenous IGFBP-2 to alter apoptosis induced by various chemotherapeutic agents. As both these cell lines produce large amounts of IGFBP-2, we also examined the effect of silencing IGFBP-2 using siRNA.

Results

In MCF7 cells, paclitaxel (50 μM) increased cell death from 9% to 24.5% (P < 0.001). Addition of IGFBP-2 (25 ng/ml) decreased the induced cell death by almost one-half to 17.7% (P = 0.047). 5-Fluorouricil (20 μM) increased cell death of T47D cells by 54% (P = 0.044), which was completely blocked by the addition of IGFBP-2. Conversely, loss of IGFBP-2 enhanced chemotherapy-induced apoptosis in both cell lines compared with a nonsilencing siRNA. We also observed that loss of IGFBP-2 reduced cellular proliferation - the live cell number decreased 73% (P < 0.001) and 33% (P < 0.001) in the MCF7 and T47D cells, respectively. Additionally, in the MCF7 cells, loss of IGFBP-2 alone increased cell death threefold (P < 0.001).

Conclusions

These data show that the production of IGFBP-2 by breast cancer cells enhances their survival and protects them against chemotherapy. Thus in breast tumours the increase in IGFBP-2 production could be a survival mechanism making IGFBP-2 a legitimate target for intervention.

Acknowledgements

This research was funded by Breast Cancer Campaign.

References

  1. Perks CM, Vernon EG, Rosenthal AH, Tonge D, Holly JM: IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells.

    Oncogene 2007, 26:5966-5972. PubMed Abstract | Publisher Full Text OpenURL